Literature DB >> 17312114

Dendritic cell function can be modulated through cooperative actions of TLR ligands and invariant NKT cells.

Ian F Hermans1, Jonathan D Silk, Uzi Gileadi, S Hajar Masri, Dawn Shepherd, Kathryn J Farrand, Mariolina Salio, Vincenzo Cerundolo.   

Abstract

The quality of signals received by dendritic cells (DC) in response to pathogens influences the nature of the adaptive response. We show that pathogen-derived signals to DC mediated via TLRs can be modulated by activated invariant NKT (iNKT) cells. DC maturation induced in vivo with any one of a variety of TLR ligands was greatly improved through simultaneous administration of the iNKT cell ligand alpha-galactosylceramide. DC isolated from animals treated simultaneously with TLR and iNKT cell ligands were potent stimulators of naive T cells in vitro compared with DC from animals treated with the ligands individually. Injection of protein Ags with both stimuli resulted in significantly improved T cell and Ab responses to coadministered protein Ags over TLR stimulation alone. Ag-specific CD8(+) T cell responses induced in the presence of the TLR4 ligand monophosphoryl lipid A and alpha-galactosylceramide showed faster proliferation kinetics, and increased effector function, than those induced with either ligand alone. Human DC exposed to TLR ligands and activated iNKT cells in vitro had enhanced expression of maturation markers, suggesting that a cooperative action of TLR ligands and iNKT cells on DC function is a generalizable phenomenon across species. These studies highlight the potential for manipulating the interactions between TLR ligands and iNKT cell activation in the design of effective vaccine adjuvants.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17312114     DOI: 10.4049/jimmunol.178.5.2721

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  28 in total

Review 1.  Immunotherapeutic strategies targeting natural killer T cell responses in cancer.

Authors:  Susannah C Shissler; Dominique R Bollino; Irina V Tiper; Joshua P Bates; Roshanak Derakhshandeh; Tonya J Webb
Journal:  Immunogenetics       Date:  2016-07-08       Impact factor: 2.846

Review 2.  Lipid antigens in immunity.

Authors:  C Marie Dowds; Sabin-Christin Kornell; Richard S Blumberg; Sebastian Zeissig
Journal:  Biol Chem       Date:  2014-01       Impact factor: 3.915

3.  The requirement of CD80, CD86, and ICAM-1 on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccine.

Authors:  George Hui; Caryn Hashimoto
Journal:  Vaccine       Date:  2007-10-26       Impact factor: 3.641

4.  Requirement for CD1d expression by B cells to stimulate NKT cell-enhanced antibody production.

Authors:  Gillian A Lang; T Scott Devera; Mark L Lang
Journal:  Blood       Date:  2007-12-12       Impact factor: 22.113

Review 5.  Harnessing invariant NKT cells in vaccination strategies.

Authors:  Vincenzo Cerundolo; Jonathan D Silk; S Hajar Masri; Mariolina Salio
Journal:  Nat Rev Immunol       Date:  2009-01       Impact factor: 53.106

Review 6.  NKT cells in liver diseases.

Authors:  Shasha Zhu; Huimin Zhang; Li Bai
Journal:  Front Med       Date:  2018-04-06       Impact factor: 4.592

Review 7.  Mucopolysaccharide diseases: a complex interplay between neuroinflammation, microglial activation and adaptive immunity.

Authors:  Louise D Archer; Kia J Langford-Smith; Brian W Bigger; James E Fildes
Journal:  J Inherit Metab Dis       Date:  2013-05-08       Impact factor: 4.982

Review 8.  Immune therapies.

Authors:  Rao H Prabhala; Nikhil C Munshi
Journal:  Hematol Oncol Clin North Am       Date:  2007-12       Impact factor: 3.722

9.  Regulatory roles for NKT cell ligands in environmentally induced autoimmunity.

Authors:  Jaya Vas; Jochen Mattner; Stewart Richardson; Rachel Ndonye; John P Gaughan; Amy Howell; Marc Monestier
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

Review 10.  The role of NKT cells in tumor immunity.

Authors:  Masaki Terabe; Jay A Berzofsky
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.